Material and financial support for the research being conducted from the HIV Cure Center comes from a broad base. UNC and ViiV, through Qura Therapeutics, a company co-founded by GSK and UNC-CH, provide financial and material support to the partnership. In October of 2018, the ViiV Healthcare Discovery Unit and GSK’s HIV Discovery Performance Unit (DPU) merged and ViiV assumed GSK roles and responsibilities as it pertains to the partnership. ViiV is contributing a team of experienced scientists with ongoing HIV cure programs and associated assets, as well as expertise and know-how in medicines discovery, drug development and manufacturing.

https://estuelke.github.io/funding.html